NHE-1 and NHE-6 Activities
Ischemic and Reperfusion Injury

H.E. Cingolani, I.L. Ennis, S.M. Mosca

The study published in this issue of Circulation Research showing that a null mutation of NHE-1 improves the tolerance of the heart to ischemia and reperfusion (I/R) is an important contribution for the following reasons: (1) In the animals with null mutation, contracture during the ischemic period was less and ATP levels were preserved compared with wild-type animals. This observation, on the one hand, provides evidence that protection by downregulation of NHE-1 during the ischemic period itself is indeed possible and, on the other hand, it argues against the suggestion that the exchanger is inactive during this same period. (2) In contrast with chronic blockade of the NHE-1 indeed possible and, on the other hand, it argues against the downregulation of NHE-1 during the ischemic period itself is during reperfusion. The increase in Ca²⁺ secondary to the increase in Na⁺ seems to be caused by the Na⁺-Ca²⁺ exchanger (NCX) working in reverse mode, and cytosolic Ca²⁺ overload is a necrotic and apoptotic signal. Although with some contradictory results, it has been possible to obtain protection from I/R by blocking the NHE-1 or the NCX only after the onset of reperfusion, suggesting that there is protection against the reperfusion injury induced by these mechanisms in addition to protection from the ischemic injury.

Although other mechanisms can be operative, the activation of NHE-1 at the onset of reperfusion has been linked to the increase in reactive oxygen species (ROS). This exchanger reaches its maximal activity early after reperfusion. It has been proposed that the increase in ROS leads to activation of the mitogen-activated protein kinase pathway, phosphorylating ERK1/2 and the cytosolic tail of the NHE-1, increasing the exchanger activity. On the other hand, it has been also reported that ERK1/2 mediates activation of the Na⁺-HCO₃⁻ cotransport and that blockade of this mechanism protects against I/R injury.

The available evidence, therefore, establishes that the cytosolic Ca²⁺ overload induced by the NCX working in its reverse mode can be prevented by blocking the NHE-1, decreasing Na⁺. A recent publication makes things more difficult to interpret. In this study, the authors showed that cariporide preserves mitochondrial proton gradient and delays ATP depletion in mouse-derived myocytes (HL-1) after simulated ischemia and suggested that these mitochondrial changes are not secondary to changes in the cytosol. They concluded that, during ischemia, cariporide acts at the mitochondrial level, delaying mitochondrial matrix acidification and preserving ATP levels. They also suggested that the prevention of mitochondrial Ca²⁺ overload was not cariporide’s mechanism of protection.

Mitochondrial NHE (MNHE) is apparently encoded by NHE-6, with a molecular structure similar to that of NHE-1. However, there are still some concerns about the identification of the NHE-6 with the MNHE. The MNHE can be blocked by several NHE blockers including cariporide; therefore, this drug blocks both the NHE-1 (sarcoplasmic) and the NHE-6 (mitochondrial) gene products.

In a more recent study, the effect of cariporide on cell death induced by oxidative stress was examined in cultured neonatal cardiomyocytes. The inhibitor suppressed cytosolic Na⁺ and Ca²⁺ accumulation and the loss of mitochondrial...
membrane potential induced by H$_2$O$_2$, while also decreasing the mitochondrial Ca$^{2+}$ overload induced by H$_2$O$_2$. Despite the decrease in cytosolic and mitochondrial Ca$^{2+}$ overload, their results suggested a contribution of two Ca$^{2+}$-independent pathways: calcium-independent cell death and calcium-independent cytochrome c release induced by the blocker. These results suggest that NHE-1 blockade preserves mitochondrial integrity after oxidant stress. These actions were not blunted by mitochondrial K$_{ATP}$ channel blockers, revealing different mechanisms of protection from those operative in ischemic preconditioning. Although some studies have suggested that NHE-1 inhibition and ischemic preconditioning are linked phenomena, this and other studies suggest that NHE inhibition preserves their results. These results suggest that NHE inhibition preserves the mitochondrial V$_{m}$.

How can we reconcile the evidence that null mutation of the NHE-1 induces protection from ischemia/reperfusion and that cariporide also protects against ischemia/reperfusion but acting on another isoform? The simplest explanation is that, although the downregulation of the NHE-1 by its ablation by genetic techniques protects the heart from ischemia/reperfusion, additional protection can be obtained by the blockade of MNHE (NHE-6) with the compound. However, the investigators did not accomplish additional protection from I/R when a blocker of the NHE-1, eniporide, was added to the animals with the null mutation of the NHE-1. Among the possibilities to understand this discrepancy, we should consider the following: first, that NHE-1 is not only the sarcolemmal isoform of the NHE but also the mitochondrial one; second, that the genetic manipulation of these animals produced an unintentional downregulation or modification of the MNHE, making it “inactive” for the ischemic/reperfusion injury; third, that the attenuation of the injury obtained with the blockade of the NHE-1 is maximal and so no further beneficial effect will be detected blocking the MNHE.

New avenues of research begin with the novel contributions of these studies about the reperfusion injury process. Should we consider the existence of two protections, one during ischemia and the other one during reperfusion, each mediated by a different NHE isoform? Is the acidification of the cytosol a change that attenuates the reperfusion injury, in contrast to the same change in the mitochondrial matrix? What is the role of NCX in cytosol and mitochondrial Ca$^{2+}$ overload? May Ca$^{2+}$ overload in one compartment protect the other? Should we consider the downregulation of the heart NHE by genetic techniques a gene therapy possibility? All are questions that should be answered in the near future. In contrast with the promising results coming from studies in several animal species and NHE inhibitors, clinical trials have not shown unequivocal evidence of this protection. The GUARDIAN, ESCAMI, and EXPEDITION trials are examples of such disappointment. The latter was started in 2001 and stopped 6 months later for reasons unreleased to the public. The strikingly beneficial effects of NHE inhibition in well-controlled experimental systems give reason to hope that future drug trials may prove the clinical utility of this therapeutic principle.

References


KEY WORDS: myocardial infarction ■ NHE-1 ■ NHE-6 ■ apoptosis ■ necrosis